MX2017016690A - Compuesto de imidazodiazepina. - Google Patents
Compuesto de imidazodiazepina.Info
- Publication number
- MX2017016690A MX2017016690A MX2017016690A MX2017016690A MX2017016690A MX 2017016690 A MX2017016690 A MX 2017016690A MX 2017016690 A MX2017016690 A MX 2017016690A MX 2017016690 A MX2017016690 A MX 2017016690A MX 2017016690 A MX2017016690 A MX 2017016690A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- dopamine
- receptor
- present
- pam
- Prior art date
Links
- -1 Imidazodiazepine compound Chemical class 0.000 title abstract 3
- 229940126027 positive allosteric modulator Drugs 0.000 abstract 5
- 102000004076 Dopamine D1 Receptors Human genes 0.000 abstract 4
- 108090000511 Dopamine D1 Receptors Proteins 0.000 abstract 4
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 2
- 208000023105 Huntington disease Diseases 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010013663 drug dependence Diseases 0.000 abstract 2
- 230000000069 prophylactic effect Effects 0.000 abstract 2
- 201000000980 schizophrenia Diseases 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se provee un compuesto el cual es útil como un modulador alostérico positivo del receptor de dopamina D1 (D1 MAP). Los presentes inventores han estudiado un compuesto el cual tiene un efecto modulador alostérico positivo (efecto MAP) sobre un receptor de dopamina D1 y el cual se puede utilizar como un ingrediente activo de una composición farmacéutica para prevenir y/o tratar el deterioro cognitivo, el síntoma negativo de la esquizofrenia, CIAS, enfermedad de Parkinson, enfermedad de Alzheimer, enfermedad de Huntington, depresión, ADHD, dependencia de fármacos o trastornos similares. Por consiguiente, se confirma que el compuesto de imidazodiazepina de la presente invención tiene un efecto MAP sobre un receptor de dopamina D1, y de ese modo completaron la presente invención. El compuesto de imidazodiazepina de la presente invención tiene un efecto MAP sobre un receptor de dopamina D1 y se prevé que sea un agente para prevenir y/o tratar el deterioro cognitivo, el síntoma negativo de la esquizofrenia, CIAS, la enfermedad de Parkinson, la enfermedad de Alzheimer, la enfermedad de Huntington, la depresión, ADHD, la dependencia de fármacos o trastornos similares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015123478 | 2015-06-19 | ||
| PCT/JP2016/068080 WO2016204268A1 (ja) | 2015-06-19 | 2016-06-17 | イミダゾジアゼピン化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017016690A true MX2017016690A (es) | 2018-03-15 |
Family
ID=57546103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016690A MX2017016690A (es) | 2015-06-19 | 2016-06-17 | Compuesto de imidazodiazepina. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10426784B2 (es) |
| EP (1) | EP3312181B1 (es) |
| JP (1) | JP6658753B2 (es) |
| KR (1) | KR102591169B1 (es) |
| CN (2) | CN111205292B (es) |
| AR (1) | AR105025A1 (es) |
| AU (1) | AU2016279518B2 (es) |
| CA (1) | CA2989982C (es) |
| CO (1) | CO2018000431A2 (es) |
| CY (1) | CY1122232T1 (es) |
| DK (1) | DK3312181T3 (es) |
| ES (1) | ES2751913T3 (es) |
| HR (1) | HRP20191961T1 (es) |
| HU (1) | HUE047430T2 (es) |
| IL (1) | IL256252B (es) |
| LT (1) | LT3312181T (es) |
| MX (1) | MX2017016690A (es) |
| MY (1) | MY197499A (es) |
| PH (1) | PH12017502253B1 (es) |
| PL (1) | PL3312181T3 (es) |
| PT (1) | PT3312181T (es) |
| RS (1) | RS59497B1 (es) |
| RU (1) | RU2712968C2 (es) |
| SG (1) | SG11201710345VA (es) |
| SI (1) | SI3312181T1 (es) |
| TW (1) | TWI697496B (es) |
| UA (1) | UA120006C2 (es) |
| WO (1) | WO2016204268A1 (es) |
| ZA (1) | ZA201708566B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| TWI725408B (zh) | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1395257A1 (en) * | 2001-06-12 | 2004-03-10 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| JP3813152B2 (ja) | 2002-03-12 | 2006-08-23 | メルク エンド カムパニー インコーポレーテッド | 置換アミド類 |
| WO2004000837A1 (ja) * | 2002-06-25 | 2003-12-31 | Sumitomo Pharmaceuticals Co., Ltd. | 新規なベンズオキサゾリノン誘導体 |
| JP4989976B2 (ja) * | 2004-02-13 | 2012-08-01 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 翻訳開始阻害剤としての３−３−二置換オキシインドール |
| CN1922141A (zh) | 2004-02-23 | 2007-02-28 | 大日本住友制药株式会社 | 新的杂环化合物 |
| JP4914346B2 (ja) * | 2004-05-27 | 2012-04-11 | ユセベ ファルマ ソシエテ アノニム | ベンズオキサゾロン誘導体、その調製方法及びその使用 |
| CL2007002097A1 (es) | 2006-07-20 | 2008-01-18 | Smithkline Beecham Corp | Compuestos derivados de pirrolidina o morfolina antagonistas de urotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar insuficiencia cardiaca congestiva, insuficiencia cardiaca isquemica, angina, isquemia del miocardio, vejiga hiperactiva, asma y/o copd, entre otras. |
| PE20081229A1 (es) * | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| WO2011163355A1 (en) * | 2010-06-24 | 2011-12-29 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors |
| AR095883A1 (es) | 2013-04-18 | 2015-11-18 | Astellas Pharma Inc | Compuestos de acetamida heterocíclica |
-
2016
- 2016-06-16 AR ARP160101804A patent/AR105025A1/es unknown
- 2016-06-17 TW TW105119205A patent/TWI697496B/zh not_active IP Right Cessation
- 2016-06-17 UA UAA201800508A patent/UA120006C2/uk unknown
- 2016-06-17 SG SG11201710345VA patent/SG11201710345VA/en unknown
- 2016-06-17 RS RS20191427A patent/RS59497B1/sr unknown
- 2016-06-17 CN CN202010083916.3A patent/CN111205292B/zh active Active
- 2016-06-17 HR HRP20191961TT patent/HRP20191961T1/hr unknown
- 2016-06-17 MY MYPI2017704807A patent/MY197499A/en unknown
- 2016-06-17 CA CA2989982A patent/CA2989982C/en active Active
- 2016-06-17 PL PL16811742T patent/PL3312181T3/pl unknown
- 2016-06-17 DK DK16811742T patent/DK3312181T3/da active
- 2016-06-17 MX MX2017016690A patent/MX2017016690A/es active IP Right Grant
- 2016-06-17 US US15/737,564 patent/US10426784B2/en active Active
- 2016-06-17 RU RU2018101861A patent/RU2712968C2/ru active
- 2016-06-17 ES ES16811742T patent/ES2751913T3/es active Active
- 2016-06-17 EP EP16811742.2A patent/EP3312181B1/en active Active
- 2016-06-17 KR KR1020177036276A patent/KR102591169B1/ko active Active
- 2016-06-17 CN CN201680034335.2A patent/CN107635996B/zh active Active
- 2016-06-17 PH PH1/2017/502253A patent/PH12017502253B1/en unknown
- 2016-06-17 LT LTEP16811742.2T patent/LT3312181T/lt unknown
- 2016-06-17 JP JP2017524854A patent/JP6658753B2/ja active Active
- 2016-06-17 AU AU2016279518A patent/AU2016279518B2/en active Active
- 2016-06-17 SI SI201630411T patent/SI3312181T1/sl unknown
- 2016-06-17 PT PT168117422T patent/PT3312181T/pt unknown
- 2016-06-17 HU HUE16811742A patent/HUE047430T2/hu unknown
- 2016-06-17 WO PCT/JP2016/068080 patent/WO2016204268A1/ja not_active Ceased
-
2017
- 2017-12-11 IL IL256252A patent/IL256252B/en active IP Right Grant
- 2017-12-15 ZA ZA2017/08566A patent/ZA201708566B/en unknown
-
2018
- 2018-01-17 CO CONC2018/0000431A patent/CO2018000431A2/es unknown
-
2019
- 2019-10-16 CY CY20191101083T patent/CY1122232T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
| NZ768373A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| NZ725008A (en) | Compounds for treating spinal muscular atrophy | |
| MX389592B (es) | Moduladores alostericos positivos del receptor m1 muscarinico | |
| ZA201907746B (en) | 6-5 fused rings as c5a inhibitors | |
| PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
| NZ759295A (en) | 5-5 fused rings as c5a inhibitors | |
| MX2016004944A (es) | Compuesto biciclico que contiene azufre. | |
| TN2016000491A1 (en) | Carboxamide derivatives. | |
| CY1119754T1 (el) | Ετεροκυκλικη ενωση αμιδιου οξικου οξεος | |
| NZ763341A (en) | Polycyclic amides as muscarinic m1 receptor positive allosteric modulators | |
| PH12017502253A1 (en) | Imidazodiazepine compound | |
| BR112017018192A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica. | |
| NZ764004A (en) | Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators | |
| PH12020500233A1 (en) | Adamantylmethylamine derivative and use thereof as pharmaceutical | |
| PH12018501563A1 (en) | Indane derivatives as mglur7 modulators | |
| MX2020000144A (es) | Composicion farmaceutica para administracion nasal. | |
| MA39901A (fr) | Antagonistes de mglu2/3 pour le traitement de troubles des facultés intellectuelles | |
| JOP20180057A1 (ar) | مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 | |
| TH183160A (th) | สารประกอบเฮตเทอโรไซคลิค อะซีทาไมด์ | |
| PH12017501209A1 (en) | Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors | |
| PH12016502247A1 (en) | Carboxamide derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |